Live Breaking News & Updates on Rev Clin Oncol

Stay updated with breaking news from Rev clin oncol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population.

Dr. Yashushi Goto a leading lung cancer. ....

United States , Exchange Commission On , Securities Exchange , American Cancer Society , Translational Lung Cancer Research , Lantern Pharma Inc , National Cancer Center , Lantern Pharma , East Asia , Translational Lung Cancer , Yashushi Goto , East Asian , Lung Cancer , Rev Clin Oncol , Never Smokers , Tyrosine Kinases , Starlight Therapeutics , Securities Act , Securities Exchange Act , Risk Factors , Annual Report , Exchange Commission , Pharma Disclosure Channels , Disseminate Information ,

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Simon Jenkins , Bella Zhou Janice Han , Eli Lilly , David Portman , Elizabeth Attias , Sotiriouc Luminal , Barry Komm , Miriam Portman , Paul Plourde , National Comprehensive Cancer Network , Parke Davis Pharmaceuticals , Duke University , Sermonixsermonix Pharmaceuticals Inc , Shanghai Henlius Biotech Inc , Ligand Pharmaceuticals Inc , Sermonix Pharmaceuticals Inc , Chinese Society Of Clinical Oncology , Pharmaceuticals Inc , Shanghai Henlius Biotech , Ping Cao , Chinese Society , Clinical Oncology , Ligand Pharmaceuticals , Sermonixsermonix Pharmaceuticals , Anthony Wild ,

Specific causes of excess late mortality and association with modifiable risk factors among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort

Survivors of childhood cancer are at excess risk of late mortality even 40 years from
diagnosis, due to many of the leading causes of death in the US population. Modifiable
lifestyle and cardiovascular risk factors associated with reduced risk for late mortality
should be part of future interventions. ....

Nordrhein Westfalen , United States , Coll Cardiol , Cardiovasc Disord , National Center , Children Oncology Group , National Cancer , Health Statistics Mortality Data , United States Department Of Health , Centers For Disease , National Cancer Institute , Human Services Centers For Disease , Englj Med , Childhood Cancer Survivor , Natl Cancer Inst , Clin Oncol , Childhood Cancer Survivor Study , National Cancer Institute Supported , Vital Stat Rep , States Department , Human Services Centers , Disease Control , Blood Cancer , Rev Clin Oncol , International Late Effects , Childhood Cancer Guideline Harmonization ,

Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement

Combined advances in haematopoietic cell transplantation (HCT) and intensive care
management have improved the survival of patients with haematological malignancies
admitted to the intensive care unit. In cases of refractory respiratory failure or
refractory cardiac failure, these advances have led to a renewed interest in advanced
life support therapies, such as extracorporeal membrane oxygenation (ECMO), previously
considered inappropriate for these patients due to their poor prognosis. Given the
scarcity of evidence-based guidelines on the use of ECMO in patients receiving HCT
and the need to provide equitable and sustainable access to ECMO, the European Society
of Intensive Care Medicine, the Extracorporeal Life Support Organization, and the
International ECMO Network aimed to develop an expert consensus statement on the use
of ECMO in adult patients receiving HCT. ....

South Korea , United States , France General , Scott Stephens , Civriz Bozda , Grupo Espa , Trasplante Hematopoyetico , Garcia Borrega , J Thorac Cardiovasc , Ann Hematol , Semin Thromb Hemost , Extracorporeal Life Support Organization Task , European Society Of Intensive Care Medicine , Extracorporeal Life Support Organization Maastricht Treaty , Marrow Transplant Research , Extracorporeal Life Support Organization Ecmoed Taskforce , International Blood , American Society For Transplantation , Lancet Child Adolesc Health , European Society Of Paediatric , Society Of Critical Care Medicine , Extracorporeal Life Support Organization , Extracorporeal Life Support Organization Registry , Health Sci Rep , Paris International Conference , Marrow Transplant ,

First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer

The treatment framework for advanced non-small-cell lung cancer harbouring anaplastic
lymphoma kinase (ALK) fusions has changed substantially since the discovery of crizotinib,
a first-generation ALK tyrosine-kinase inhibitor (TKI). Three generations of ALK TKIs
have since been developed, with increasing potency, CNS penetrance, and ability to
overcome ALK-resistance mutations with each successive generation.1 Multiple phase
3 trials have shown superior efficacy of second-generation ALK TKIs (alectinib, brigatinib,
and ensartinib) compared with crizotinib, establishing next-generation ALK TKIs as
preferred initial therapy. ....

Rev Clin Oncol ,